From: Doctors’ preferences in de-escalating DMARDs in rheumatoid arthritis: a discrete choice experiment
Group 1 n = 48 | Group 2 n = 22 | Group 3 n = 26 | Group 4 n = 30 | Group 5 n = 30 | p * | |
---|---|---|---|---|---|---|
Age (years), median (IQR) | 43 (35–51) | 49 (40–56) | 39 (35–45) | 50 (40–60) | 41 (37–52) | 0.038 |
Female, n (%) | 22 (51%) | 12 (55%) | 15 (60%) | 15 (50%) | 20 (67%) | 0.663 |
Trainee, n (%) | 11 (26%) | 2 (9%) | 7 (29%) | 1 (3%) | 7 (26%) | 0.051 |
Work experience (years), median (IQR) | 7 (0–15) | 13 (5–25) | 5 (0–8) | 12 (5–25) | 4 (0–18) | 0.027 |
Self-reported number of RA patients in practice, median (IQR) | 375 (100–800) | 425 (200–1100) | 450 (100–2000) | 300 (200–1000) | 300 (100–500) | 0.492 |
Self-reported prevalence of biological treatment among RA patients in practice, median (IQR) | 23 (20–30) | 20 (20–33) | 30 (20–30) | 29 (20–33) | 20 (15–30) | 0.641 |
Working in academic hospital, n (%) | 9 (21%) | 4 (18%) | 6 (24%) | 5 (17%) | 7 (23%) | 0.955 |
No data, n (%) | 5 (10%) | 0 (0%) | 2 (8%) | 1 (3%) | 3 (10%) | <0.001 |